ClariVest Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

ClariVest Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$2.29M	Hold	14,469	–	–	0.23%	118
2024 Q2	$2.29M	Buy	14,469 +39	+0.3%	+$5.01K	0.23%	118
2024 Q1	$1.87M	Sell	14,430 -129	-0.9%	-$15.8K	0.19%	154
2023 Q4	$1.4M	Sell	14,559 -12	-0.1%	-$1.15K	0.08%	186
2023 Q3	$1.77M	Buy	14,571 +21	+0.1%	+$2.37K	0.1%	135
2023 Q2	$1.67M	Sell	14,550 -3,004	-17%	-$387K	0.08%	155
2023 Q1	$2.42M	Sell	17,554 -17	-0.1%	-$2.21K	0.11%	152
2022 Q4	$2.28M	Sell	17,571 -69	-0.4%	-$8K	0.11%	147
2022 Q3	$1.95M	Buy	+17,640	New	+$1.78M	0.09%	167
2021 Q3	–	Sell	-10,700	Closed	-$832K	–	819
2021 Q2	$832K	Hold	10,700	–	–	0.03%	330
2021 Q1	$798K	Sell	10,700 -100	-0.9%	-$9.23K	0.03%	325
2020 Q4	$1.84M	Sell	10,800 -400	-4%	-$59.3K	0.06%	221
2020 Q3	$1.57M	Hold	11,200	–	–	0.05%	254
2020 Q2	$1.8M	Buy	+11,200	New	+$1.52M	0.05%	245
2017 Q1	–	Sell	-13,931	Closed	-$382K	–	744
2016 Q4	$382K	Buy	+13,931	New	+$560K	0.01%	427
2016 Q1	–	Sell	-23,717	Closed	-$915K	–	663
2015 Q4	$915K	Buy	+23,717	New	+$769K	0.03%	294

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

ClariVest Asset Management's SRPT Position: Q3 2024 in Review

ClariVest Asset Management held its Sarepta Therapeutics (SRPT) position steady in Q3 2024 at 14,469 shares worth $2.29M. The position accounts for 0.23% of the portfolio, ranked #118.

ClariVest Asset Management first reported a position in SRPT in Q4 2015 and has held it in 16 quarters since. The position peaked at $2.42M in Q1 2023. 458 funds tracked by Wall St. Rank hold SRPT as of Q3 2024.

ClariVest Asset Management held 14,469 shares of Sarepta Therapeutics worth $2.29M as of Q3 2024.
ClariVest Asset Management left its Sarepta Therapeutics share count unchanged in Q3 2024.
Sarepta Therapeutics made up 0.23% of ClariVest Asset Management's portfolio in Q3 2024, its #118 holding.
ClariVest Asset Management first reported a position in Sarepta Therapeutics in Q4 2015 and has held it in 16 quarters since.
ClariVest Asset Management's Sarepta Therapeutics position peaked at $2.42M in Q1 2023.
458 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2024.

Based on ClariVest Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.